<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: SkinBioTherapeutics agree psoriasis treatment deal with Winclove Probiotics BV	</title>
	<atom:link href="https://ukinvestormagazine.co.uk/skinbiotherapeutics-agree-psoriasis-treatment-deal-with-winclove-probiotics-bv/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestormagazine.co.uk/skinbiotherapeutics-agree-psoriasis-treatment-deal-with-winclove-probiotics-bv/</link>
	<description>UK Investor Magazine provides breaking financial news and investment ideas</description>
	<lastBuildDate>Tue, 03 Mar 2020 13:33:08 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.5</generator>
	<item>
		<title>
		By: SkinBioTherapeutics widen loss in first half due to higher R&#38;D costs - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/skinbiotherapeutics-agree-psoriasis-treatment-deal-with-winclove-probiotics-bv/#comment-14610</link>

		<dc:creator><![CDATA[SkinBioTherapeutics widen loss in first half due to higher R&#38;D costs - UK Investor Magazine]]></dc:creator>
		<pubDate>Tue, 03 Mar 2020 13:33:08 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=27274#comment-14610</guid>

					<description><![CDATA[[&#8230;] life sciences firm told shareholders that it had seen a pretax loss of £889,002 within the six month period which [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] life sciences firm told shareholders that it had seen a pretax loss of £889,002 within the six month period which [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
